Lineage Cell Therapeutics (LCTX) Invested Capital (2013 - 2021)

Lineage Cell Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $152000.0 for Q3 2023.

• In Q3 2023, Invested Capital rose 270.73% year-over-year to $152000.0; the TTM figure through Jun 2024 stood at $152000.0 (down 69.9% YoY), while the FY2022 annual figure was $113000.0, up 213.89% from the prior year.
• Invested Capital for Q3 2023 stood at $152000.0, down from $167000.0 in the prior quarter.
• The five-year high for Invested Capital was $184000.0 in Q1 2023, with the low at $29000.0 in Q3 2021.
• The 5-year median for Invested Capital is $75000.0 (2020), against an average of $85500.0.
• The sharpest annual moves came in 2021 and 2023: Invested Capital plunged 64.52% in 2021, then jumped 270.73% in 2023.
• Lineage Cell Therapeutics' Invested Capital stood at $110000.0 in 2019, then tumbled by 61.82% to $42000.0 in 2020, then decreased by 14.29% to $36000.0 in 2021, then jumped by 213.89% to $113000.0 in 2022, then soared by 34.51% to $152000.0 in 2023.
• Business Quant data shows LCTX's Invested Capital at $152000.0 in Q3 2023, $167000.0 in Q2 2023, and $184000.0 in Q1 2023.